2026-10-14T05:00:52Z https://api.figshare.com/v2/oai

oai:figshare.com:article/34021779 2026-09-29T07:08:39Z category_7 category_12 category_39 category_734 category_64 category_106 category_128 portal_87 item_type_6 month_year_09_2026

Cost-effectiveness of Orca-T vs allo-HCT with conventional GVHD prophylaxis for the treatment of advanced hematologic malignancies in the United States Rawan Faramand (15021294) James Scott McClellan (25135854) Anna Pavlova (2610877) Rocio Manghani (17632727) Andrea Blank (25135857) Matia Saeedian (22698907) Shivani Yadav (12159236) Miguel-Angel Perales (496837) Medicine Cell Biology Ecology Biological Sciences not elsewhere classified Cancer Science Policy Hematology Cost-effectiveness allogeneic hematopoietic cell transplantation graft-versus-host disease post-transplant cyclophosphamide hematological malignancies United States mixture cure model I11 D61 I18 <p>Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative therapy for patients with hematologic malignancies, but its success is limited by graft‑versus‑host disease (GVHD), which carries considerable clinical and economic burden. A cost-effectiveness model was developed to evaluate whether the higher upfront costs of allogeneic regulatory T cell-based immunotherapy with HSPC and T cells-vldq (Tregzi [Orca-T; Orca Bio, Menlo Park, CA, USA]) are offset by reductions in GVHD and associated healthcare costs compared with conventional allo-HCT using TAC/MTX or PTCy.</p> <p>A three-state partitioned survival model (relapse-free, relapsed, and dead) with a lifetime horizon and monthly cycles was developed. Overall survival and relapse-free survival data from the Phase 3 Precision-T study (ClinicalTrials.gov Identifier NCT05316701) were incorporated using a cure-mixture modeling approach to estimate long-term survival, relapse status, and cure fraction for patients. Costs included transplant procedure, GVHD management, infection management, and terminal care. Outcomes included life-years, quality-adjusted life-years (QALYs), and direct healthcare costs. Both costs and outcomes were discounted at 3% annually. A scenario analysis was conducted to determine the cost-effectiveness of Orca-T vs allo-HCT with PTCy for GVHD prophylaxis, and sensitivity analyses were conducted to test the uncertainty of the model inputs.</p> <p>Orca‑T was associated with lower lifetime costs ($1,026,856 vs $2,170,875) and higher QALYs (15.28 vs 13.00) than conventional allo‑HCT with TAC/MTX, yielding cost savings of $1,144,019 and a gain of 2.28 QALYs per patient. GVHD-related costs were substantially lower with Orca‑T ($495,447 vs $1,998,621). Compared with PTCy, Orca‑T remained dominant, with cost savings of $158,144, a gain of 2.85 QALYs, and lower GVHD-related costs ($476,448 vs $999,945).</p> <p>Orca‑T reduced costs and increased QALYs versus conventional allo‑HCT with TAC/MTX or PTCy, driven by lower GVHD and infection burden. These findings support Orca‑T as a high‑value treatment option.</p> 2026-09-29T07:08:39Z Text Journal contribution 10.6084/m9.figshare.34021779.v1 https://figshare.com/articles/journal_contribution/Cost-effectiveness_of_Orca-T_vs_allo-HCT_with_conventional_GVHD_prophylaxis_for_the_treatment_of_advanced_hematologic_malignancies_in_the_United_States/34021779 CC BY 4.0